These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 21559452)

  • 21. The monoclonal antibody CH12 enhances the sorafenib-mediated growth inhibition of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III.
    Yang Y; Jiang H; Gao H; Kong J; Zhang P; Hu S; Shi B; Zhang P; Yao M; Li Z
    Neoplasia; 2012 Jun; 14(6):509-18. PubMed ID: 22787432
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sorafenib: scientific rationales for single-agent and combination therapy in clear-cell renal cell carcinoma.
    Gollob JA
    Clin Genitourin Cancer; 2005 Dec; 4(3):167-74. PubMed ID: 16425993
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MiRNA-30a-mediated autophagy inhibition sensitizes renal cell carcinoma cells to sorafenib.
    Zheng B; Zhu H; Gu D; Pan X; Qian L; Xue B; Yang D; Zhou J; Shan Y
    Biochem Biophys Res Commun; 2015 Apr; 459(2):234-239. PubMed ID: 25712526
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diffuse-type gastric carcinoma: progression, angiogenesis, and transforming growth factor beta signaling.
    Komuro A; Yashiro M; Iwata C; Morishita Y; Johansson E; Matsumoto Y; Watanabe A; Aburatani H; Miyoshi H; Kiyono K; Shirai YT; Suzuki HI; Hirakawa K; Kano MR; Miyazono K
    J Natl Cancer Inst; 2009 Apr; 101(8):592-604. PubMed ID: 19351925
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sorafenib attenuates p21 in kidney cancer cells and augments cell death in combination with DNA-damaging chemotherapy.
    Inoue H; Hwang SH; Wecksler AT; Hammock BD; Weiss RH
    Cancer Biol Ther; 2011 Nov; 12(9):827-36. PubMed ID: 21878748
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sorafenib inhibits neuroblastoma cell proliferation and signaling, blocks angiogenesis, and impairs tumor growth.
    Kakodkar NC; Peddinti RR; Tian Y; Guerrero LJ; Chlenski A; Yang Q; Salwen HR; Maitland ML; Cohn SL
    Pediatr Blood Cancer; 2012 Oct; 59(4):642-7. PubMed ID: 22147414
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of angiogenic and non-angiogenic targets by sorafenib in renal cell carcinoma (RCC) in a RCC xenograft model.
    Yuen JS; Sim MY; Siml HG; Chong TW; Lau WK; Cheng CW; Huynh H
    Br J Cancer; 2011 Mar; 104(6):941-7. PubMed ID: 21407223
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib.
    Zimmermann K; Schmittel A; Steiner U; Asemissen AM; Knoedler M; Thiel E; Miller K; Keilholz U
    Oncology; 2009; 76(5):350-4. PubMed ID: 19321976
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination of the ERK inhibitor AZD6244 and low-dose sorafenib in a xenograft model of human renal cell carcinoma.
    Yuen JS; Sim MY; Sim HG; Chong TW; Lau WK; Cheng CW; Ong RW; Huynh H
    Int J Oncol; 2012 Aug; 41(2):712-20. PubMed ID: 22641227
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sorafenib enhances the antitumor effects of chemoradiation treatment by downregulating ERCC-1 and XRCC-1 DNA repair proteins.
    Yadav A; Kumar B; Teknos TN; Kumar P
    Mol Cancer Ther; 2011 Jul; 10(7):1241-51. PubMed ID: 21551262
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells.
    Bareford MD; Hamed HA; Tang Y; Cruickshanks N; Burow ME; Fisher PB; Moran RG; Nephew KP; Grant S; Dent P
    Autophagy; 2011 Oct; 7(10):1261-2. PubMed ID: 21814046
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors.
    Lierman E; Lahortiga I; Van Miegroet H; Mentens N; Marynen P; Cools J
    Haematologica; 2007 Jan; 92(1):27-34. PubMed ID: 17229632
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel combination therapy with imiquimod and sorafenib for renal cell carcinoma.
    Karashima T; Komatsu T; Niimura M; Kawada C; Kamada M; Inoue K; Udaka K; Kuroda N; Shuin T
    Int J Urol; 2014 Jul; 21(7):702-6. PubMed ID: 24571181
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination of Temsirolimus and tyrosine kinase inhibitors in renal carcinoma and endothelial cell lines.
    Martin B; Edeline J; Patard JJ; Oger E; Jouan F; Boulanger G; Zerrouki S; Vigneau C; Rioux-Leclercq N
    J Cancer Res Clin Oncol; 2012 Jun; 138(6):907-16. PubMed ID: 22322364
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of mechanism involved in acquired resistance to sorafenib in a mouse renal cell cancer RenCa model.
    Harada K; Miyake H; Kusuda Y; Fujisawa M
    Clin Transl Oncol; 2014 Sep; 16(9):801-6. PubMed ID: 24356934
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long noncoding RNA-SRLR elicits intrinsic sorafenib resistance via evoking IL-6/STAT3 axis in renal cell carcinoma.
    Xu Z; Yang F; Wei D; Liu B; Chen C; Bao Y; Wu Z; Wu D; Tan H; Li J; Wang J; Liu J; Sun S; Qu L; Wang L
    Oncogene; 2017 Apr; 36(14):1965-1977. PubMed ID: 27841868
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of sorafenib and sunitinib in the induction of expressions of NKG2D ligands in nasopharyngeal carcinoma with high expression of ABCG2.
    Huang Y; Wang Y; Li Y; Guo K; He Y
    J Cancer Res Clin Oncol; 2011 May; 137(5):829-37. PubMed ID: 20809412
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab.
    Garcia JA; Hutson TE; Elson P; Cowey CL; Gilligan T; Nemec C; Dreicer R; Bukowski RM; Rini BI
    Cancer; 2010 Dec; 116(23):5383-90. PubMed ID: 20806321
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
    La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
    Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition.
    Allen E; Walters IB; Hanahan D
    Clin Cancer Res; 2011 Aug; 17(16):5299-310. PubMed ID: 21622725
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.